All articles by Drug Target Review – Page 28
-
News
Scientists discover key to long COVID lung damage and potential treatment
Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune cells’ ability to repair lung tissue.
-
ArticleThe future of mental health treatment: Zelquistinel's role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
-
NewsFirst AI-designed drug, Rentosertib, officially named by USAN
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
-
ArticleNew insights into surfactant spread for lung drug delivery
A recent study led by Dr Richard McNair highlights the role of the Marangoni effect in surfactant spreading, offering potential improvements in drug development and delivery for lung diseases.
-
NewsScientists turn superbug MRSA into treatable infection
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
-
NewsAWS and ElevateBio join forces to advance gene editing
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
-
NewsBacterial ‘jumping genes’ found to control chromosome ends
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
ArticleEmpowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
-
NewsGoogle’s AI co-scientist accelerates drug development
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
-
ArticleHope for ALS and inflammatory diseases: Cellenkos' CRANE technology breakthrough
Cellenkos' CRANE technology, led by Dr Simrit Parmar, harnesses regulatory T cells to precisely target and treat inflammatory diseases. This innovative approach offers hope for conditions like aplastic anaemia, myelofibrosis, and ALS.
-
NewsNew AI algorithm searches 10 sextillion drug candidates
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
-
ArticleThe future of cell therapy: scaling production for global reach
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
-
NewsAI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
-
ArticleObesity care gets personalised: tailoring therapies with Phenomix
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
-
Article
Building better brain models for Parkinson’s disease and beyond
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
-
NewsNew genetic discovery offers hope for arthritis drug development
York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment.
-
NewsGinger-based compound targets inflammation in IBD
Researchers at the University of Toronto have discovered a compound in ginger, furanodienone (FDN), that interacts with the pregnane X receptor to reduce inflammation in the colon. This finding suggests FDN could be an effective, natural treatment for inflammatory bowel disease (IBD).
-
NewsNew gene identified for treating malignant cardiac arrhythmias
Researchers have identified a small gene, SCN10a-short, that could enable gene therapy to treat malignant cardiac arrhythmias. This discovery offers the potential for a one-time treatment, reducing the reliance on lifelong medication and invasive procedures.
-
NewsBlood pressure drug shows promise in ADHD symptom reduction
A study by the University of Surrey suggests that amlodipine, a common blood pressure medication, could be repurposed as a safer, more accessible treatment for ADHD. This offers a promising alternative to current medications and highlights the potential of drug repurposing in advancing treatment options.
